Cholinergic Urticaria - Efficacy of Dupilumab

  • STATUS
    Recruiting
  • days left to enroll
    89
  • participants needed
    72
  • sponsor
    Charite University, Berlin, Germany
Updated on 23 January 2021

Summary

The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with cholinergic urticarial (CholU) who are symptomatic despite H1-antihistamine treatment (licensed dose).

Description

Treatment with Dupilumab has been shown to reduce clinically significant exacerbations and to improve skin symptom control as well as quality of life in moderate to severe atopic dermatitis patients and in moderate to severe asthma patients. It has been approval by EMA for the treatment of atopic dermatitis patients in September 2017.

Dupilumab is a novel monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in atopic dermatitis and asthma. Considering that CholU and atopic diseases share many common features (e.g. key pathogenic role of mast cells and IgE, itch is a dominant symptom, Th2 dominance), it is reasonable to expect that Dupilumab is beneficial in CholU.

These results suggest that Dupilumab may provide an effective treatment option for patients with insufficient treatment responses to H1-antihistamines exhibiting wheal and flare type skin reactions.

The gold standard treatment of CholU consists of administration of antihistamines. In most patients, symptoms persist with standard dosing of antihistamines. In antihistamine-refractory patients with cholinergic urticaria, no other licensed treatment is currently available. In 2014, omalizumab has been licensed for add-on therapy in CSU patients who still have symptoms despite standard-dosed antihistamine treatment, but not for chronic inducible forms of urticaria. Accordingly, there is still a great medical need for additional treatment options of CholU patients that are refractory to antihistamine treatment.

Dupilumab has excellent potential to provide symptom control in CholU. This study will provide additional valuable insights into the therapeutic potential of Dupilumab in improving quality of life in these patients, in addition to managing CholU symptoms.

Details
Condition Cholinergic Urticaria
Treatment Placebo, Dupilumab
Clinical Study IdentifierNCT03749148
SponsorCharite University, Berlin, Germany
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Gender: Male or Female
Do you have Cholinergic Urticaria?
Do you have any of these conditions: Do you have Cholinergic Urticaria??
Diagnosis: cholinergic urticaria (ongoing disease)
Patient is informed about study procedures and medications and has given written informed consent before any assessment
Patient is able to communicate with the investigator, understands and complies with the requirements of the study
Male or Female
Patient is 18-75 years of age
Patient is diagnosed with CholU and refractory to standard of care treatment at the time of randomization, as defined by the following
The presence of itch and hives for equal or more than 6 consecutive weeks at
any time prior to enrollment despite current use of licensed dose H1
antihistamine Urticaria control test UCT less than 12 prior to randomization
(Day 1) CholU diagnosis for 6 months
\. Willing and able to complete a daily symptom diary for the duration of the
study and adhere to the study visit schedules
\. Patients must not have more than one missing diary entry in the 7 days
prior to randomization. Re-screening may be considered
\. Women of childbearing potential have to agree to use an acceptable form of
contraception (as determined by the site investigator) and have to continue
its use for the duration of the study

Exclusion Criteria

Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations
History of hypersensitivity to any of the study drugs (Dupilumab, rescue medication) or their components or to drugs of similar chemical classes
Clearly dominating other form of urticaria as etiology for wheal and flare type reactions. This includes the following: Chronic spontaneous urticaria, inducible urticaria: urticaria factitia, cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic, or contact-urticaria. These diseases are allowed as comorbidities, if cholinergic urticaria is the dominating form of chronic urticaria
Other diseases with symptoms of urticaria or angioedema, including urticaria vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)
Any other skin disease associated with chronic itching that might confound the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, etc.)
Patients who have received concomitant prohibited medication within the last 3 months prior to screening
Anti-IgE therapy (e.g. omalizumab)
Routine (daily or every other day during 5 or more consecutive days) doses of systemic corticosteroids or other immunosuppressants
Intravenous immunoglobulins
Biological therapy
Systemic immunosuppressants
Live/attenuated vaccines
Other investigational drugs
Use of prohibited treatment detailed in protocol (see section 6.5.8 and Table 3: Prohibited treatment)
History of anaphylactic shock
Presence of hypereosinophilic diseases (blood eosinophils >1500 cells/mm3 at the latest available test)
Presence of clinically significant cardiovascular, bronchial, neurological, psychiatric, metabolic or other pathological conditions that could interfere with the interpretation of the study results and/or compromise the safety of the patients
Medical examination or laboratory findings that suggest the possibility of decompensation of co-existing conditions for the duration of the study. Any items that are cause for uncertainty must be reviewed with the Medical Monitor
Inability to comply with study and follow-up procedures
History of malignancy of any organ system (other than localized basal cell carcinoma or actinic keratosis or Bowen disease: carcinoma in situ of skin; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
Evidence of severe renal dysfunction at screening
Patient considered potentially unreliable or where it is envisaged the patient may not consistently attend scheduled study visits
Serious psychiatric and/or psychological disturbances
History or evidence of ongoing drug or alcohol abuse, within the last 6 months prior to randomization
Patient unable to complete a patient diary or complete questionnaires on paper
Any other condition or prior/current treatment, which in the opinion of the investigator renders the patient ineligible for the study schedule
Study personnel or first degree relatives of investigator(s) must not be included in the study
Subjects who live in detention on court order or on regulatory action as per local and national law (see 40 subsection 1 sentence 3 no. 4 Arzneimittelgesetz)
Pregnant or nursing (lactating) women, where pregnancy is defined
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are using highly-effective methods of contraception during the duration of the study. Highly-effective contraception methods include
Total abstinence (when this is in line with the preferred and usual lifestyle of the patient), Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment
Male sterilization (at least 6 m prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient
Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception
Placement of an intrauterine device (IUD) or intrauterine system (IUS) In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment
Note: Women are considered post-menopausal and not of child bearing potential
if they have had 12 months of natural (spontaneous) amenorrhea with an
appropriate clinical profile (e.g. age appropriate, history of vasomotor
symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40
mIU/mL; or have had surgical bilateral oophorectomy (with or without
hysterectomy) at least six months ago. In the case of oophorectomy alone, only
when the reproductive status of the woman has been confirmed by follow up
hormone level assessment is she considered not of child bearing potential
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note